Benjamin Burnett
Stock Analyst at Wells Fargo
(3.56)
# 888
Out of 5,112 analysts
89
Total ratings
55.38%
Success rate
5.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Benjamin Burnett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVDL Avadel Pharmaceuticals | Maintains: Equal-Weight | $20 → $23 | $21.40 | +5.14% | 3 | Nov 20, 2025 | |
| CNTA Centessa Pharmaceuticals | Maintains: Overweight | $30 → $35 | $25.29 | +38.39% | 3 | Nov 13, 2025 | |
| ALKS Alkermes | Maintains: Overweight | $42 → $37 | $28.18 | +31.30% | 3 | Nov 13, 2025 | |
| AXSM Axsome Therapeutics | Maintains: Overweight | $163 → $157 | $147.92 | +6.14% | 2 | Nov 4, 2025 | |
| FATE Fate Therapeutics | Maintains: Hold | $5 → $3 | $1.06 | +183.02% | 3 | Mar 6, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $53 → $49 | $56.03 | -12.54% | 6 | Feb 13, 2025 | |
| ACLX Arcellx | Maintains: Buy | $83 → $122 | $64.95 | +87.84% | 5 | Oct 18, 2024 | |
| BEAM Beam Therapeutics | Maintains: Buy | $66 → $69 | $26.23 | +163.06% | 2 | Sep 11, 2024 | |
| IDYA IDEAYA Biosciences | Maintains: Buy | $63 → $68 | $33.87 | +100.77% | 7 | Sep 10, 2024 | |
| ALLO Allogene Therapeutics | Maintains: Hold | $4.4 → $4.6 | $1.45 | +217.24% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $120 → $58 | $17.22 | +233.91% | 4 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $690 → $780 | $4.77 | +16,252.20% | 2 | Sep 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $217 → $234 | $162.82 | +43.72% | 1 | Dec 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $48 | $43.08 | +11.43% | 3 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $29 | $15.80 | +83.54% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $8 | $5.98 | +33.89% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $23 | $20.50 | +12.20% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $73 → $93 | $74.87 | +24.22% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $414 → $423 | $510.21 | -17.09% | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $64 | $76.77 | -16.63% | 5 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $90 → $94 | $89.54 | +4.99% | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $4 | $2.19 | +83.07% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $10 | $4.01 | +149.38% | 3 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $2.59 | +865.25% | 11 | Sep 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $330 → $360 | $44.00 | +718.18% | 2 | Jun 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $16 | $0.45 | +3,430.45% | 1 | Jan 6, 2021 |
Avadel Pharmaceuticals
Nov 20, 2025
Maintains: Equal-Weight
Price Target: $20 → $23
Current: $21.40
Upside: +5.14%
Centessa Pharmaceuticals
Nov 13, 2025
Maintains: Overweight
Price Target: $30 → $35
Current: $25.29
Upside: +38.39%
Alkermes
Nov 13, 2025
Maintains: Overweight
Price Target: $42 → $37
Current: $28.18
Upside: +31.30%
Axsome Therapeutics
Nov 4, 2025
Maintains: Overweight
Price Target: $163 → $157
Current: $147.92
Upside: +6.14%
Fate Therapeutics
Mar 6, 2025
Maintains: Hold
Price Target: $5 → $3
Current: $1.06
Upside: +183.02%
CRISPR Therapeutics AG
Feb 13, 2025
Maintains: Hold
Price Target: $53 → $49
Current: $56.03
Upside: -12.54%
Arcellx
Oct 18, 2024
Maintains: Buy
Price Target: $83 → $122
Current: $64.95
Upside: +87.84%
Beam Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $66 → $69
Current: $26.23
Upside: +163.06%
IDEAYA Biosciences
Sep 10, 2024
Maintains: Buy
Price Target: $63 → $68
Current: $33.87
Upside: +100.77%
Allogene Therapeutics
May 14, 2024
Maintains: Hold
Price Target: $4.4 → $4.6
Current: $1.45
Upside: +217.24%
Apr 1, 2024
Maintains: Hold
Price Target: $120 → $58
Current: $17.22
Upside: +233.91%
Sep 10, 2021
Maintains: Buy
Price Target: $690 → $780
Current: $4.77
Upside: +16,252.20%
Dec 16, 2025
Maintains: Overweight
Price Target: $217 → $234
Current: $162.82
Upside: +43.72%
Dec 11, 2025
Maintains: Overweight
Price Target: $44 → $48
Current: $43.08
Upside: +11.43%
Dec 9, 2025
Maintains: Overweight
Price Target: $16 → $29
Current: $15.80
Upside: +83.54%
Nov 11, 2025
Maintains: Overweight
Price Target: $10 → $8
Current: $5.98
Upside: +33.89%
Nov 11, 2025
Maintains: Overweight
Price Target: $26 → $23
Current: $20.50
Upside: +12.20%
Nov 5, 2025
Maintains: Overweight
Price Target: $73 → $93
Current: $74.87
Upside: +24.22%
Oct 30, 2025
Maintains: Equal-Weight
Price Target: $414 → $423
Current: $510.21
Upside: -17.09%
Apr 1, 2025
Maintains: Buy
Price Target: $78 → $64
Current: $76.77
Upside: -16.63%
Jan 24, 2025
Maintains: Buy
Price Target: $90 → $94
Current: $89.54
Upside: +4.99%
Dec 13, 2024
Maintains: Buy
Price Target: $9 → $4
Current: $2.19
Upside: +83.07%
Jun 3, 2024
Maintains: Buy
Price Target: $7 → $10
Current: $4.01
Upside: +149.38%
Sep 15, 2023
Reiterates: Buy
Price Target: $25
Current: $2.59
Upside: +865.25%
Jun 28, 2021
Upgrades: Buy
Price Target: $330 → $360
Current: $44.00
Upside: +718.18%
Jan 6, 2021
Initiates: Hold
Price Target: $16
Current: $0.45
Upside: +3,430.45%